Study guide
3.1 Peptic Ulcer Disease & Upper GI Bleeding
Combined Medical Services Examination UPSC CMS
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Exam Structure, Logistics & Pattern
1.1 UPSC CMS Examination Overview & Eligibility 1.2 Two-Paper Written Exam Pattern & Negative Marking 1.3 Personality Test, Service Allocation & Career Paths
2 Chapter 2: General Medicine - Cardiology & Respiratory
2.1 Coronary Artery Disease & Acute Myocardial Infarction 2.2 Heart Failure & Cardiac Arrhythmias 2.3 Community-Acquired Pneumonia & Pulmonary Tuberculosis 2.4 COPD, Bronchial Asthma & Pulmonary Embolism
3 Chapter 3: General Medicine - Gastroenterology & Hepatology
3.1 Peptic Ulcer Disease & Upper GI Bleeding 3.2 Liver Cirrhosis & Portal Hypertension 3.3 Acute & Chronic Viral Hepatitis & Pancreatitis 3.4 Inflammatory Bowel Disease & Malabsorption Syndromes
4 Chapter 4: General Medicine - Nephrology & Endocrinology
4.1 Acute Kidney Injury & Chronic Kidney Disease 4.2 Glomerulonephritis, Nephrotic Syndrome & Electrolyte Imbalances 4.3 Diabetes Mellitus: Diagnosis, Complications & Management 4.4 Thyroid Disorders & Adrenal Gland Dysfunction
5 Chapter 5: General Medicine - Neurology, Haematology & Infection
5.1 Cerebrovascular Accidents (Stroke) & Epilepsy 5.2 Approach to Anaemia: Microcytic, Megaloblastic & Haemolytic 5.3 Acute & Chronic Leukaemias and Lymphomas 5.4 Tropical & Endemic Infections: Malaria, Typhoid & Dengue
6 Chapter 6: General Medicine - Emergency Medicine & Toxicology
6.1 Acute Anaphylaxis, Sepsis & Cardiopulmonary Resuscitation 6.2 Organophosphate, Paracetamol & Snakebite Toxicology 6.3 Common Dermatological & Psychiatric Manifestations in Internal Medicine 6.4 Musculoskeletal System & Adult Rheumatology
7 Chapter 7: Paediatrics - Neonatology & Child Growth
7.1 Newborn Care, Neonatal Resuscitation & APGAR Score 7.2 Prematurity, Low Birth Weight & Neonatal Jaundice 7.3 Infant & Child Growth & Developmental Milestones
8 Chapter 8: Paediatrics - Child Health & Nutrition
8.1 Protein-Energy Malnutrition (PEM) & Micronutrient Deficiencies 8.2 Universal Immunization Programme (UIP) & Child Vaccines 8.3 Pediatric Diarrhoea, Dehydration & Respiratory Emergencies 8.4 Birth Defects, Genetic Counseling, Autism & Paediatric Accidents/Poisoning
9 Chapter 9: Surgery - General Surgery, Wounds & Shock
9.1 Wound Healing, Surgical Site Infections & Gas Gangrene 9.2 Pathophysiology of Shock & Perioperative Fluid Therapy 9.3 Acute Abdomen: Appendicitis, Peritonitis & Intestinal Obstruction 9.4 Classification, Resuscitation & Management of Thermal Burns 9.5 Medicolegal & Ethical Issues in Surgery
10 Chapter 10: Surgery - Surgical Specialties I
10.1 Inguinal, Femoral & Ventral Hernias 10.2 Benign Breast Diseases & Breast Carcinoma 10.3 Solitary Thyroid Nodule & Thyroid Carcinoma 10.4 Benign Prostatic Hyperplasia & Renal Calculi
11 Chapter 11: Surgery - ENT, Orthopaedics & Anaesthesia
11.1 Acute Otitis Media, Tonsillitis & Epistaxis 11.2 Cataract, Glaucoma & Red Eye Emergencies 11.3 Principles of Fracture Management & Common Dislocation 11.4 Principles of Local, Regional & General Anaesthesia 11.5 Neurosurgery: Raised ICP, Head Injury & CNS Lesions 11.6 Thoracic Surgery: Chest Trauma, Pleural & Lung Disease
12 Chapter 12: Obstetrics - Antenatal Care & Complications
12.1 Antenatal Care, Maternal Nutrition & Fetal Assessment 12.2 Preeclampsia, Eclampsia & Gestational Hypertension 12.3 Antepartum Haemorrhage: Placenta Previa & Abruptio Placentae 12.4 Anemia in Pregnancy & Gestational Diabetes Mellitus 12.5 Spontaneous & Recurrent Abortion: Recognition & Management
13 Chapter 13: Obstetrics & Gynaecology - Labor & PPH
13.1 Normal Labor Mechanisms & Partograph Monitoring 13.2 Malpresentations, Breech & Obstructed Labor 13.3 Postpartum Haemorrhage (PPH) Causes & Management 13.4 Puerperal Sepsis & Postnatal Maternal Care
14 Chapter 14: Gynaecology & Family Planning
14.1 Abnormal Uterine Bleeding & Uterine Fibroids 14.2 Cervical Screening (Pap Smear) & Pelvic Inflammatory Disease 14.3 Temporary & Permanent Contraceptive Methods in India 14.4 Medical Termination of Pregnancy (MTP): Law & Methods
15 Chapter 15: PSM - Epidemiology & Biostatistics
15.1 Principles of Epidemiology & Disease Transmission 15.2 Observational & Experimental Epidemiological Study Designs 15.3 Evaluation of Screening Tests: Sensitivity, Specificity & Predictive Value 15.4 Biostatistics: Sampling, Central Tendency & Significance Testing
16 Chapter 16: PSM - Disease Epidemiology & Programmes
16.1 Epidemiology & Control of TB, Malaria & Dengue 16.2 National Tuberculosis Elimination Programme & NVBDCP 16.3 Epidemiology of Hypertension, Diabetes & Cancer in India 16.4 Cold Chain Management & Vaccine Logistics in India 16.5 Genetics and Health: Inheritance, Screening & Counseling
17 Chapter 17: PSM - Health Planning & Environmental Health
17.1 Demography, Fertility Rates & Family Welfare Indicators 17.2 Safe Water Supply, Waste Disposal & Air Pollution 17.3 Occupational Health Hazards & Pneumoconioses 17.4 Health Care Delivery System, Ayushman Bharat & National Health Mission 17.5 International Health: WHO, Global Agencies & SDG 3 17.6 Medical Sociology & Health Education
3.1 Peptic Ulcer Disease & Upper GI Bleeding
Key Takeaways Explain This Topic AI
Helicobacter pylori infection and nonsteroidal anti-inflammatory drugs (NSAIDs) account for over 90% of peptic ulcer disease (PUD) cases.
Diagnostic testing for H. pylori via Urea Breath Test or Stool Antigen requires withholding proton pump inhibitors (PPIs) for 2 weeks and antibiotics for 4 weeks to prevent false-negative results.
Upper GI bleeding (UGIB) management prioritizes hemodynamic resuscitation with a restrictive blood transfusion strategy (target Hb 7-9 g/dL) followed by early endoscopically guided intervention within 24 hours.
The Forrest classification categorizes endoscopic ulcer bleeding lesions into high-risk (Ia, Ib, IIa), intermediate-risk (IIb), and low-risk (IIc, III) to guide endotherapy and post-procedure monitoring.
Zollinger-Ellison syndrome (ZES) should be suspected in refractory or multiple jejunal ulcers, diagnosed by fasting serum gastrin >1000 pg/mL and secretin stimulation testing.
Last updated: July 2026
Peptic Ulcer Disease & Upper GI Bleeding
Peptic ulcer disease (PUD) represents a mucosal break of ≥ 5 mm \ge 5\text{ mm} ≥ 5 mm in diameter in the stomach or duodenum that penetrates through the muscularis mucosae. In UPSC Combined Medical Services (CMS) examinations, high-yield questions focus on distinguishing gastric from duodenal ulcers, understanding Helicobacter pylori diagnostic nuances, mastering the Forrest classification, and implementing acute resuscitation protocols for upper gastrointestinal bleeding (UGIB).
Etiopathogenesis of Peptic Ulcer Disease
Gastric mucosal integrity depends on a balance between aggressive factors (acid, pepsin, H. pylori , NSAIDs, bile salts) and protective defenses (mucus-bicarbonate barrier, mucosal blood flow, epithelial renewal, prostaglandin E 2 \text{E}_2 E 2 and I 2 \text{I}_2 I 2 ).
1. Helicobacter pylori Infection
Microbiology: Gram-negative, microaerophilic, flagellated curved bacillus residing in the non-acid-secreting gastric mucus layer.
Pathogenic Virulence Factors:
Urease enzyme: Hydrolyzes urea into ammonia and CO 2 \text{CO}_2 CO 2 , neutralizing gastric acid locally to create a protective microenvironment.
CagA (Cytotoxin-associated gene A): Translocated into epithelial cells via a Type IV secretion system, inducing interleukin-8 (IL-8) secretion, neutrophil infiltration, and oncogenic signaling.
VacA (Vacuolating cytotoxin A): Forms pores in epithelial cell membranes, inducing cell vacuolation and apoptosis.
Pattern of Gastritis & Ulcer Disease:
Antral-predominant gastritis: Increases gastrin secretion (via destruction of somatostatin-producing D cells in the antrum), leading to hypergastrinemia, increased parietal cell mass, elevated basal acid output, and duodenal ulceration .
Pangastritis / Corpus-predominant gastritis: Causes parietal cell atrophy and hypochlorhydria, predisposing to gastric ulceration and gastric adenocarcinoma.
2. NSAID-Induced Ulceration
Mechanism: Systemic inhibition of Cyclooxygenase-1 (COX-1) blocks the synthesis of mucosal protective prostaglandins ( PGE 2 \text{PGE}_2 PGE 2 and PGI 2 \text{PGI}_2 PGI 2 ). This reduces gastric mucus and bicarbonate secretion, decreases mucosal blood flow, and impairs platelet aggregation.
Risk Factors: Age > 65 >65 > 65 years, prior PUD/bleeding, high-dose NSAIDs, concomitant systemic corticosteroids, anticoagulants, or antiplatelet agents (e.g., aspirin, clopidogrel).
3. Zollinger-Ellison Syndrome (ZES / Gastrinoma)
Severe PUD caused by a gastrin-secreting neuroendocrine tumor located in the Gastrinoma Triangle (Passaro Triangle) : bounded by the junction of the cystic and common bile ducts superiorly, second/third portion of the duodenum inferiorly, and neck/body of the pancreas medially.
Manifests with multiple refractory ulcers (often involving the distal duodenum or jejunum), severe diarrhea, and hypertrophic gastric folds.
Clinical Distinctions: Duodenal vs. Gastric Ulcers
- Clinical Parameter Duodenal Ulcer (DU) Gastric Ulcer (GU)
- Incidence / Age 4 times more common; peak age 30–50 years Peak age 55–70 years
- Acid Secretion Elevated or normal basal acid output Normal or decreased acid output
Pain Characteristics Pain 1.5–3 hours after meals; relieved by food/antacids Pain immediately or 30 min after meals; aggravated by food
- Nocturnal Pain Common (wakes patient between 12 AM and 3 AM) Uncommon
- Weight Changes Weight gain (eating relieves pain) Weight loss (fear of food / anorexia)
- Location First part of duodenum (duodenal bulb, anterior wall) Less curvature of stomach (incisura angularis)
Malignant Potential Exceptionally rare (<0.01%) 2–5% risk (requires multiple biopsies at index EGD & repeat EGD to confirm healing)
Complication Profiles Anterior wall DU → \rightarrow → Perforation; Posterior wall DU → \rightarrow → Bleeding (erosion into Gastroduodenal Artery) Bleeding (erosion into Left Gastric Artery)
- Diagnostic Workup for H. pylori
- Non-Invasive Diagnostic Tests
13 C \text{}^{13}\text{C} 13 C or 14 C \text{}^{14}\text{C} 14 C Urea Breath Test (UBT): Gold-standard non-invasive test. Patient ingests labeled urea; bacterial urease cleaves it into labeled CO 2 \text{CO}_2 CO 2 , measured in exhaled breath. Sensitivity and specificity > 95 % >95\% > 95% .
Stool Antigen Test (SAT): Enzyme immunoassay detecting H. pylori antigen in stool. Excellent for primary diagnosis and confirming post-treatment eradication (at least 4 weeks post-therapy).
Serology (IgG antibodies): Cannot distinguish active from past resolved infection (remains positive for years). Not recommended for confirming eradication.
Critical Clinical Rule for UPSC CMS: Proton pump inhibitors (PPIs) must be discontinued for at least 14 days , and antibiotics/bismuth compounds for at least 28 days prior to performing a UBT, Stool Antigen Test, or Rapid Urease Test. Failure to withhold these medications leads to false-negative results due to temporary suppression of bacterial load.
Invasive Tests (Endoscopy-Based)
Rapid Urease Test (RUT / CLOtest): Gastric antral biopsy placed in a urea-rich gel containing phenol red pH indicator. Bacterial urease converts urea to ammonia → \rightarrow → raising pH → \rightarrow → color change from yellow to magenta.
Histology: Modified Giemsa or Warthin-Starry silver stain permits direct visualization of bacilli and assessment of mucosal inflammation.
Eradication Regimens for H. pylori
Standard Bismuth Quadruple Therapy (First-line where clarithromycin resistance > 15 % >15\% > 15% ):
PPI (Standard dose BID) + Bismuth subsalicylate (524 mg QID) + Metronidazole (500 mg TID-QID) + Tetracycline (500 mg QID) for 14 days .
Concomitant Non-Bismuth Quadruple Therapy:
PPI (BID) + Amoxicillin (1000 mg BID) + Clarithromycin (500 mg BID) + Metronidazole (500 mg BID) for 14 days .
Acute Upper Gastrointestinal Bleeding (UGIB)
UGIB is defined as intraluminal bleeding originating proximal to the ligament of Treitz (duodenojejunal flexure). PUD accounts for ≈ 50 % \approx 50\% ≈ 50% of non-variceal UGIB cases.
Hemodynamic Resuscitation & Triage
Airway & Access: Protect airway in altered sensorium; establish two large-bore peripheral IV lines (16G or 14G).
Fluid Resuscitation: Crystalloids (Normal Saline or Ringer's Lactate) to maintain mean arterial pressure (MAP) ≥ 65 mmHg \ge 65\text{ mmHg} ≥ 65 mmHg .
Restrictive Blood Transfusion Strategy: Transfuse Packed Red Blood Cells (PRBCs) at a hemoglobin threshold of < 7 g/dL <7\text{ g/dL} < 7 g/dL , targeting a post-transfusion Hb level of 7 − 9 g/dL 7-9\text{ g/dL} 7 − 9 g/dL . (A higher threshold of < 8 g/dL <8\text{ g/dL} < 8 g/dL applies to patients with active ischemic cardiovascular disease).
Risk Stratification Scores:
Glasgow-Blatchford Score (GBS): Pre-endoscopic score utilizing blood urea, hemoglobin, systolic BP, pulse, melena, syncope, hepatic disease, and cardiac failure. A score of 0–1 identifies low-risk patients suitable for outpatient management without urgent EGD.
Rockall Score: Incorporates age, shock, comorbidities, endoscopic findings, and stigmata of recent hemorrhage to predict rebleeding risk and mortality.
Endoscopic Stigmata: Forrest Classification
During esophagogastroduodenoscopy (EGD), ulcer bases are classified according to the Forrest criteria, which directly determine the need for endoscopic hemostatic therapy and predict rebleeding rates.
- Forrest Class Endoscopic Description Rebleeding Risk (Without Endotherapy) Recommended Management
- Ia Active spurting arterial hemorrhage 80–90% Immediate Dual Endoscopic Therapy + IV PPI
- Ib Active oozing hemorrhage 55–60% Immediate Dual Endoscopic Therapy + IV PPI
- IIa Non-bleeding visible vessel 40–50% Dual Endoscopic Therapy + IV PPI
- IIb Adherent clot over ulcer base 20–30% Clot removal by irrigation ± \pm ± therapy of underlying lesion
- IIc Flat pigmented / black spot 7–10% Medical therapy (Oral PPI); No endoscopic therapy
- III Clean, white ulcer base 3–5% Medical therapy (Oral PPI); Early hospital discharge
- Endoscopic Hemostasis Techniques
Dual therapy is superior to monotherapy: Submucosal Epinephrine injection (1:10,000 dilution; provides initial mechanical tamponade and vasoconstriction) PLUS a second mechanical or thermal modality (e.g., Hemoclips, Bipolar electrocautery, Argon Plasma Coagulation).
Pharmacotherapy: High-dose IV PPI (e.g., Omeprazole 80 mg IV bolus followed by 8 mg/hour continuous IV infusion for 72 hours) stabilizes the fibrin clot by maintaining intragastric pH > 6.0 \text{pH} > 6.0 pH > 6.0 .